| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.37B | 63.51B | 54.47B | 52.03B | 51.61B | 52.32B |
| Gross Profit | 8.20B | 8.96B | 8.45B | 8.13B | 8.12B | 8.07B |
| EBITDA | 878.50M | 1.68B | 1.38B | 2.33B | 2.69B | 2.62B |
| Net Income | -800.00M | -367.00M | -351.00M | 333.00M | 447.00M | 426.00M |
Balance Sheet | ||||||
| Total Assets | 31.10B | 31.92B | 29.49B | 23.42B | 23.75B | 24.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.24B | 4.92B | 7.15B | 4.74B | 3.99B | 4.60B |
| Total Debt | 14.25B | 14.28B | 12.75B | 9.14B | 9.91B | 10.70B |
| Total Liabilities | 24.10B | 25.01B | 22.05B | 16.43B | 17.05B | 18.39B |
| Stockholders Equity | 6.95B | 6.87B | 7.36B | 6.88B | 6.61B | 6.22B |
Cash Flow | ||||||
| Free Cash Flow | 349.50M | 609.00M | 2.10B | 1.98B | 247.00M | 1.39B |
| Operating Cash Flow | 427.00M | 1.31B | 2.71B | 2.52B | 713.00M | 1.95B |
| Investing Cash Flow | -1.29B | -4.46B | -3.12B | -703.00M | -292.00M | -1.08B |
| Financing Cash Flow | 1.95B | 939.00M | 2.77B | -1.07B | -1.03B | -728.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ¥19.36B | 6.76 | ― | 1.85% | 3.70% | 37.00% | |
| ― | ¥14.46B | 11.97 | ― | 2.40% | 5.93% | -36.11% | |
| ― | ¥11.21B | 15.39 | ― | 1.23% | 4.08% | 51.63% | |
| ― | ¥41.28B | 9.21 | ― | 1.34% | 7.12% | 14.14% | |
| ― | ¥6.16B | ― | ― | 2.61% | 15.66% | 56.93% | |
| ― | ¥19.49B | ― | ― | 3.70% | 15.00% | -195.87% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Pharmarise Holdings Corporation reported a significant increase in its financial performance for the first three months of the fiscal year ending May 31, 2026, with net sales rising by 10% year-on-year. Despite a net loss attributable to owners of the parent, the company achieved substantial growth in operating and ordinary profit, indicating improved operational efficiency and market positioning. The company’s financial outlook for the fiscal year remains positive, with expected growth in net sales and profits, reflecting its strategic focus on enhancing shareholder value.
The most recent analyst rating on (JP:2796) stock is a Hold with a Yen520.00 price target. To see the full list of analyst forecasts on Pharmarise Holdings Corp. stock, see the JP:2796 Stock Forecast page.